跳至主要内容
临床试验/NL-OMON46104
NL-OMON46104招募中不适用

Generation of circulating tumor cell derived organoids through enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancer - Circle study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 79 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
79

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - metastasized prostate cancer
  • - age * 18 years
  • - Written informed consent of the patient
  • - * 2 adequate peripheral veins as access point for leukapheresis

排除标准

  • - CTC count of < 5 CTCs/7.5 mL of blood
  • - Patients with a known hypersensitivity to the used LA-anticoagulant
  • - mHSPC patients with current ADT
  • - Hemorrhage disease and/or coagulation disorder
  • - Inadequate liver and/or renal function
  • - Inadequate hematology and coagulation status
  • - Chronic viral infections

研究者

相似试验